The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent dilution. Predicted molecular weight: 14 kDa.
p53/TP53-regulated repressor of Akt/AKT1 signaling. Represses AKT1 by preventing AKT1-binding to membrane lipids, thereby inhibiting AKT1 translocation to the cellular membrane and activation. Contributes to p53/TP53-dependent apoptosis by repressing AKT1 activity. Its directs transcription regulation by p53/TP53 may explain how p53/TP53 can negatively regulate AKT1. May acts as a tumor suppressor.
Widely expressed with lowest expression in liver and spleen.
Belongs to the PHLDA3 family. Contains 1 PH domain.
The PH domain binds phosphoinositides with a broad specificity. It competes with the PH domain of AKT1 and directly interferes with AKT1 binding to phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate (PIP3), preventing AKT1 association to membrane lipids and subsequent activation of AKT1 signaling.
Pleckstrin homology like domain family A member 2 antibody
Pleckstrin homology like domain family A member 3 antibody
Pleckstrin homology-like domain family A member 3 antibody
TDAG51/Ipl homolog 1 antibody
TDAG51/Ipl homologue 1 antibody
TIH 1 antibody
Western blot - PHLDA3 antibody [4B6] (ab81464)
Western blotting was performed using ab81464 to detect PHLDA3 protein expression. PHLDA3 protein was induced by Ad-p53 in MDA-MB-468 cells (left). PHLDA3 expression was inhibited by shRNA targeting PHLDA3 (right).